Lifecore Biomedical (NASDAQ:LFCR) Earns Outperform Rating from Barrington Research

Lifecore Biomedical (NASDAQ:LFCR)‘s stock had its “outperform” rating reissued by analysts at Barrington Research in a report issued on Tuesday,Benzinga reports. They currently have a $5.50 target price on the stock. Barrington Research’s price target would indicate a potential upside of 31.26% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd. Zacks Research upgraded Lifecore Biomedical to a “hold” rating in a report on Thursday, January 1st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Lifecore Biomedical currently has a consensus rating of “Hold” and an average target price of $5.50.

Lifecore Biomedical Stock Up 4.8%

Shares of NASDAQ:LFCR opened at $4.19 on Tuesday. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.67 and a current ratio of 2.80. Lifecore Biomedical has a 1 year low of $3.87 and a 1 year high of $8.98. The stock has a market capitalization of $157.04 million, a P/E ratio of -4.28 and a beta of 0.62. The stock has a 50-day simple moving average of $7.04 and a 200-day simple moving average of $7.32.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $35.75 million during the quarter, compared to analysts’ expectations of $35.31 million. Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. Equities analysts forecast that Lifecore Biomedical will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Lifecore Biomedical

Several hedge funds and other institutional investors have recently bought and sold shares of LFCR. Grizzlyrock Capital LLC bought a new stake in shares of Lifecore Biomedical in the second quarter worth $5,964,000. Invesco Ltd. bought a new stake in shares of Lifecore Biomedical in the 2nd quarter worth about $3,081,000. Squarepoint Ops LLC increased its position in shares of Lifecore Biomedical by 385.9% in the 3rd quarter. Squarepoint Ops LLC now owns 150,909 shares of the company’s stock worth $1,111,000 after purchasing an additional 119,851 shares during the last quarter. Millennium Management LLC raised its stake in shares of Lifecore Biomedical by 86.2% in the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock valued at $2,059,000 after purchasing an additional 116,500 shares in the last quarter. Finally, Greenhaven Road Investment Management L.P. lifted its position in shares of Lifecore Biomedical by 2.2% during the second quarter. Greenhaven Road Investment Management L.P. now owns 3,694,832 shares of the company’s stock worth $30,002,000 after purchasing an additional 78,686 shares during the last quarter. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.